More than 37 million adults in the U.S. are estimated to have some form of chronic kidney disease (CKD). Due to vague symptoms, 9 in 10 adults with CKD don’t know they have it until it’s too late, often leading to an unplanned “crash” into dialysis. Managing members with this complex disease is costly and challenging for health insurance providers.
Early stage interventions are the most effective mechanism to slow CKD progression and shift the standard of care from unplanned dialysis starts to prevention-focused, holistic care. Increased collaborations between nephrologists and kidney care providers, as well as payment models that incentivize value over volume, are essential to the success of these interventions. The move to value-based kidney care one possible solution. Through collaboration with both health insurance providers and the government, there are new opportunities to care for patients earlier in their kidney care journey.
In this session, panelists will highlight lessons learned from the first year of a groundbreaking commercial partnership, including initial participation trends, feedback from a growing community of nephrologists, and the evolution predictive analytics to deliver well-coordinated care. Panelists will also explore their approach to CMS’ Comprehensive Kidney Care Contracting (CKCC) model, in which kidney care providers assume responsibility for a patient’s care from late stage CKD through dialysis and post-transplant. The program is scheduled to launch January 1, 2022.
Chief Development Officer
DaVita Kidney Care
Misha Palecek currently serves as the Chief Transformation Officer for DaVita’s U.S. Kidney Care business. In his role, Misha is responsible for growth via strategic value-based care partnerships, mergers and acquisitions, joint venture partnerships, and care delivery innovations across the kidney care continuum.
Misha joined DaVita Kidney Care in 2005 as Director of Business Planning. In that role, he focused on driving strategy, growth and operational excellence reporting directly to the CEO. Between 2008 and 2010, he served as regional operations director, group regional operations director and divisional vice president, leading operations and growth planning for a growing portfolio of dialysis facilities on the West Coast. In 2010, Misha became group vice president responsible for over 120 dialysis facilities in Northern California as well as overseeing DaVita’s national strategy, operations and vendor relationships for home dialysis.
Misha earned his MBA from the Stanford University Graduate School of Business and his BA in Human Biology with a minor in Economics from Stanford University.
Rajiv R. Shah, MD
Founder and CEO
Dr. Shah is the Founder and CEO of MyMeds, and a practicing nephrologist at InterMed Consultants in Minneapolis. Combining his front-line experience as a physician, learnings from patients and caregivers, and his entrepreneurial zeal to improve healthcare with common sense solutions, he is focused on the importance of a personalized patient experience and its impact on value-based care.
His 2015 TEDx talk, The New Disrupters in Healthcare: Patients and Pharmacists, established him as an early thought leader in the medication experience field. He recognized that changing healthcare behaviors of people with chronic conditions requires a team-based approach that includes patients, family caregivers, and pharmacists. He has been the keynote speaker for many organizations, including the American Pharmacists Association.
He has been recognized for his work in business, medicine, and philanthropy by the Virginia McKnight Binger Award in Human Service, 40 Under 40, Outstanding Young Minnesotans, Leaders in Healthcare, and Real Power 50.
Dr. Shah graduated from Boston University with a BA in Cognitive Psychology and received his MD from the University of Minnesota Medical School.
Amy Schuerman-Gen, MD
DaVita Integrated Kidney Care
Amy Schuerman-Gen, MD is Vice President of Integrated Kidney Care at DaVita, where she oversees the clinical aspects of government IKC programs and assists with nurse practitioner and care team activities. She led a small community nephrology practice in central California and served as the Medical Director of an in-center dialysis clinic as well as a peritoneal dialysis clinic.
She completed her internal medicine and nephrology fellowship in Denver and Boston.
Mark Steffen, MD, MPH
Vice President & Chief Medical Officer
Blue Cross and Blue Shield of Minnesota
As Vice President and Chief Medical Officer of Blue Cross and Blue Shield of Minnesota, Dr. Mark Steffen oversees medical and care management strategies that encompass the organization’s medical policies; quality and clinical programs; pharmacy; and clinical products. Dr. Steffen is also responsible for leading health care quality and affordability initiatives within the company’s medical management programs.
Dr. Steffen came to Blue Cross in 2018 from Humana, where as a Medical Director he focused on population health and value-based care for patients with chronic kidney disease and end-stage renal disease.
Dr. Steffen received his bachelor’s degree in biochemistry from the University of Minnesota Duluth and both his medical degree and master’s in public health from the University of Minnesota.